Apricoxib

Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).^[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.^[2] It was also studied in clinical trials for non-small-cell lung cancer.^[3] Development was abandoned in 2015 due to poor clinical trial results.^[4]

Apricoxib

Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide
CAS Number	197904-84-0
PubChem CID	9820073
DrugBank	DB12378
ChemSpider	7995822
UNII	5X5HB3VZ3Z
KEGG	D08657
CompTox Dashboard (EPA)	DTXSID60173502
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.44 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23) Key:JTMITOKKUMVWRT-UHFFFAOYSA-N